Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...14881489149014911492149314941495149614971498...15771578»
  • ||||||||||  Journal:  Superficial Soft-Tissue Sarcomas Rarely Require Advanced Soft-Tissue Reconstruction following Resection. (Pubmed Central) -  Dec 24, 2017   
    Although concern about the morbidity associated with a free tissue transfer (ie, advanced reconstructive procedure) may potentially limit the adequacy of resection in some patients with S-STS, the results of this study showed that the majority of patients had complete excisions with negative margins and primary closure. Obtaining a negative margin when excising a known or suspected S-STS rarely requires an advanced reconstructive procedure and almost never results in loss of limb.
  • ||||||||||  dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
    Trial termination, Trial primary completion date:  ODSH + ICE Chemotherapy in Pediatric Solid Tumors (clinicaltrials.gov) -  Dec 22, 2017   
    P1,  N=4, Terminated, 
    The observed median PFS and overall survival in this large, international study can serve as a benchmark for future studies of doxorubicin in metastatic soft tissue sarcoma. Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2017; low accrual
  • ||||||||||  Review, Journal:  Cancer of the Peripheral Nerve in Neurofibromatosis Type 1. (Pubmed Central) -  Dec 21, 2017   
    In this review, we discuss the current state-of-the-art treatments for MPNSTs, latest therapeutic developments, and critical aspects of the underlying molecular and pathophysiology that appear promising for therapeutic developments in the future. In particular, we discuss the specific elements of cancer in the peripheral nerve and how that may impel development of unique therapies for this form of sarcoma.
  • ||||||||||  Votrient (pazopanib) / Novartis, BeiGene, sapanisertib (CB-228) / Calithera
    Enrollment open, Metastases:  Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma (clinicaltrials.gov) -  Dec 21, 2017   
    P2,  N=137, Recruiting, 
    In particular, we discuss the specific elements of cancer in the peripheral nerve and how that may impel development of unique therapies for this form of sarcoma. Suspended --> Recruiting
  • ||||||||||  RRx-001 / EpicentRx
    Biomarker, Preclinical, Journal:  Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. (Pubmed Central) -  Dec 20, 2017   
    The T150 min of CHP-100 tumors recovered to baseline by 24 h post-drug, suggesting a robust anti-oxidant response to the RRx-001 challenge that was presaged by a marked increase in perfusion at 1 h post-drug measured by DCE-MRI. MRI enhanced with Gd-LC7-SH provides a mechanistically rational biomarker of RRx-001 pharmacodynamics.
  • ||||||||||  dovitinib (TKI258) / Novartis, Oncoheroes
    Trial completion, Trial primary completion date:  Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma (clinicaltrials.gov) -  Dec 19, 2017   
    P2,  N=33, Completed, 
    Active, not recruiting --> Terminated Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2015
  • ||||||||||  alisertib (MLN8237) / Puma
    Trial completion, Trial primary completion date, Metastases:  Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) -  Dec 19, 2017   
    P2,  N=72, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2015 Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Trial primary completion date, Combination therapy, Monotherapy:  A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) -  Dec 19, 2017   
    P1b,  N=40, Recruiting, 
    Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Dec 2015 --> Nov 2017 | Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Dec 2015 --> Nov 2017 | Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Dec 2015 --> Nov 2017 Trial primary completion date: Jul 2018 --> Mar 2018
  • ||||||||||  Trial completion, Enrollment change:  Cytological Diagnosis of Hepatic Angiosarcoma and Its Histopathologic Correlation (clinicaltrials.gov) -  Dec 18, 2017   
    P=N/A,  N=13, Completed, 
    Trial primary completion date: Jul 2018 --> Mar 2018 Not yet recruiting --> Completed | N=50 --> 13 | Not yet recruiting --> Completed | N=50 --> 13 | Not yet recruiting --> Completed | N=50 --> 13
  • ||||||||||  Journal:  Comprehensive Analysis of Hypermutation in Human Cancer. (Pubmed Central) -  Dec 17, 2017   
    The order of mutational signatures identified previous treatment and germline replication repair deficiency, which improved management of patients and families. These data will inform tumor classification, genetic testing, and clinical trial design.
  • ||||||||||  Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
    Trial primary completion date, Combination therapy, Stroma, Metastases:  BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) -  Dec 15, 2017   
    P1/2,  N=62, Active, not recruiting, 
    ω-3 supplementation decreased Il-6 concentrations among HIV and HHV-8 co-infected Ugandans, which may have clinical benefit for KS patients. Trial primary completion date: Oct 2017 --> Oct 2018
  • ||||||||||  Journal:  Primary Undifferentiated Pleomorphic Sarcoma of the Penis. (Pubmed Central) -  Dec 14, 2017   
    The tumor was surgically excised, but the patient experienced local recurrence and, despite receiving chemotherapy and surgery, died of metastatic disease 15 months after initial presentation. Vigilance regarding biopsy and intervention for penile nodules may lead to early diagnosis and improved clinical outcomes.
  • ||||||||||  cytarabine / Generic mfg.
    Review, Journal:  Extramedullary acute myelogenous leukemia. (Pubmed Central) -  Dec 13, 2017   
    Cytarabine-based remission induction regimens have been the most commonly used in the upfront setting...In this manuscript, we will review the recent literature about EM AML, focusing on therapy and proposing a treatment algorithm for managing this rare form of leukemia. Further studies addressing risk stratification, role of molecular and genetic aberrations, and optimal treatment strategies are warranted.
  • ||||||||||  Clinical protocol, Enrollment change:  Eligibility Screening for the NIH Intramural Research Program Clinical Protocols (clinicaltrials.gov) -  Dec 13, 2017   
    P=N/A,  N=20000, Recruiting, 
    Further studies addressing risk stratification, role of molecular and genetic aberrations, and optimal treatment strategies are warranted. N=15000 --> 20000
  • ||||||||||  Journal:  Pencil Beam Scanning Proton Therapy for Rhabdomyosarcoma of the Biliary Tract. (Pubmed Central) -  Dec 13, 2017   
    Motion management and anatomical variations, such as intestinal filling or weight loss, requiring routine dosimetric evaluation and possible adaptive treatment planning, present challenges for the use of proton therapy. By taking advantage of the superior dose distribution of proton radiation, assessing the impact of tumor and anatomy motion, and performing regular dose evaluations, biliary tract RMS is an ideal diagnosis for pencil beam scanning proton therapy.
  • ||||||||||  pomalidomide / Generic mfg.
    Trial primary completion date:  Pomalidomide for Kaposi Sarcoma in People With or Without HIV (clinicaltrials.gov) -  Dec 11, 2017   
    P1/2,  N=40, Recruiting, 
    Trial primary completion date: Aug 2019 --> Dec 2019 Trial primary completion date: Dec 2017 --> Dec 2020
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker:  GEMMK: Pembrolizumab and Gemcitabine Chemotherapy in Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma (clinicaltrials.gov) -  Dec 11, 2017   
    P1/2,  N=24, Recruiting, 
    Recruiting --> Suspended Not yet recruiting --> Recruiting | Initiation date: Jul 2017 --> Nov 2017 | Trial primary completion date: Jan 2019 --> Dec 2019
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial primary completion date:  Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma (clinicaltrials.gov) -  Dec 8, 2017   
    P1/2,  N=26, Not yet recruiting, 
    These findings provide new insights into the role played by glutamine metabolism in NF1 associated tumors and strongly warrant further investigation as a potential therapy in the NF1 disease setting. Trial primary completion date: Oct 2022 --> Jun 2019